MENLO PARK, Calif. (AP) ¿ Drug developer Corcept Therapeutics Inc. said Tuesday its third-quarter loss narrowed on lower costs and expenses.

The company lost $4.7 million, or 9 cents per share, compared with a loss of $5.6 million, or 11 cents per share, during the same period a year prior. Corcept reported no revenue during the quarter, compared with $66,000 a year prior.

Analysts polled by Thomson Reuters expected a loss of 10 cents per share.

Operating expenses fell 6 percent to $4.7 million.

The company is developing Corlux as a treatment for the psychotic features of depression and for Cushing Syndrome, which is a hormone disorder.

Shares of Corcept fell 1 cent to $2.22 in midday trading.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

What's Behind the Surge in Energy Stocks

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform